Hims & Hers Health stock rallied on Canaccord Genuity’s raised price target of $40, marking the Street-high call for the telehealth company. Analyst Maria Ripps lifted the target from $32 while maintaining a Buy rating, citing the company’s progress in transitioning from compounded to branded weight loss drugs and strong partnerships with major pharmaceutical players.

The stock currently trades at $34.67, with analyst targets ranging from $21 to $40, reflecting divergent views on the company’s valuation and growth prospects. HIMS shares rose approximately 67% in the second quarter alone, signaling strong investor confidence in the company’s strategic direction.

Momentum from Strategic Partnerships and Sales Growth

Hims’…